Aronson was previously a health policy adviser to Rahm Emanuel when he served in the House of Representatives.
The House’s most powerful Democrat teaming up with insurers on drug prices may make it harder to consider more aggressive changes down the road.
Already, the House has taken the side of pharmacy benefit managers in a dispute with the Trump administration over drug company rebates.
One of Aronson’s clients is the Pharmaceutical Care Management Association, the leading trade group for pharmacy benefit managers.
There’s also an exploitable split between U.S.-owned drugmakers, who oppose any regulation on drug prices, and European-owned firms, who are more comfortable with it.